Med-IQ
Capacity Building in Hepatitis C: Choosing and Optimizing Treatment
Webcast Webcast

Capacity Building in Hepatitis C: Choosing and Optimizing Treatment


Presented by the AGA Institute and Med-IQ.

Duke MedicineMed-IQ

Time to Complete:
30 minutes
Released:
8/19/16
Expires:
8/18/17
PDF:

Maximum Credits:

0.5 AMA PRA Category 1 Credit(s)
0.5 American Association of Nurse Practitioners (AANP)

Webcast Webcast
Time to Complete:
30 minutes

Released:
8/19/16

Expires:
8/18/17

PDF:

Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)
0.5 American Association of Nurse Practitioners (AANP)
Share on:
Webcast Webcast

Share on:


Time to Complete:
30 minutes
Released:
8/19/16
Expires:
8/18/17
PDF:


Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)
0.5 American Association of Nurse Practitioners (AANP)


Overview: In this Webcast, faculty discuss the most recent developments in the treatment of chronic hepatitis C virus (HCV), as well as their own frontline perspectives and barriers they encounter in practice. Data from clinical studies involving treatment-naïve and -experienced patients with HCV are also explored. Faculty also focus on the impact of cirrhosis on treatment decisions for patients with HCV.

Faculty

April G. Morris, NP

Liver Institute of Virginia

Richmond, VA

Gina Storrs, RN, CNP

Certified Adult Nurse Practitioner

Minnesota Gastroenterology PA

St. Paul, MN

Paul Kwo, MD

Professor of Medicine

Chief of Hepatology

Stanford University

Stanford, CA


Disclosure Policy

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

April G. Morris, NP
Consulting fees/advisory boards: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc.
 
Gina Storrs, RN, CNP

Consulting fees/advisory boards: AbbVie Inc., Gilead Sciences, Inc., Merck & Co., Inc.

Paul Kwo, MD
Consulting fees/advisory boards: Abbott Laboratories, AbbVie Inc., Alnylam Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc.
Fees received for promotional/non-CME activities: Innovia
Contracted research: AbbVie Inc., Bristol-Myers Squibb, Conatus Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc.

The peer reviewers and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by educational grants from AbbVie and Gilead Sciences, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.